Up-regulation of Bax-interacting factor-1 in Iranian Colorectal Cancer Patients
AbstractBackground: Colorectal cancer (CRC) is one of the most common cancers worldwide and can be caused by a variety of genetic and acquired/environmental factors. Bax-interacting factor-1 (Bif-1) is an apoptosis inducer gene that interacts with the Bcl2 protein family and triggers apoptosis via direct contact or by changing into the Bax protein conformation using the phosphorylation mechanism. Bif-1 also interacts with Beclin-1, a protein that plays a central role in autophagy through mediation of UVRAG (ultraviolet irradiation resistant-associated gene), a positive regulator of phosphatidylinositol 3-kinase complex 3 (PI3KC3), thereby inducing autophagy in mammalian cells. Considering the dual role of Bif-1 in many tumors of different origins, in this study we assessed Bif-1 gene expression to investigate its potential role as a possible prognostic biomarker in Iranian colorectal cancer patients. Methods: Bif-1 gene expression in tumors and normal adjacent tissues in 50 colorectal cancer patients were quantified using Real-time RT-PCR. Also, the association between Bif-1 gene expression levels with the histopathological characteristics of patients was assessed. Results: The results indicated an overall upregulation of the Bif-1 gene in colorectal tumors compared with normal adjacent tissues (p < 0.0001). Also, Bif-1expression was significantly elevated in stages II and III compared with stage I, and down-regulated in stage IV patients with distant metastasis. A positive association was also observed between lymph node involvement and tumor size ≥ 5 centimeters with Bif-1 overexpression (P < 0.001). Conclusion: In conclusion, up-regulation of the Bif-1 gene could be considered as a possible prognostic candidate in colorectal cancers associated with nodal metastasis and greater tumor size. Further validation of these results are recommended in studies with larger sample sizes.
Yang J, Du XL, Li S, et al.The risk and survival outcome of subsequent primary colorectal cancer after the first primary colorectal cancer: cases from 1973 to 2012. BMC Cancer. 2017;17:783.
Ko YH, Cho YS, Won HS, et al. Stage-stratified analysis of prognostic significance of Bax-interacting factor-1 expression in resected colorectal cancer. Biomed Res Int. 2013; 2013:329839.
Takahashi Y, Tsotakos N, Liu Y, et al. The Bif-1-Dynamin 2 membrane fission machinery regulates Atg9-containing vesicle generation at the Rab11-positive reservoirs. Oncotarget. 2016; 7:20855-68.
Coppola D, Khalil F, Eschrich S, Boulware D, Yeatman T, Wang HG. Down Regulation of Bax-Interacting Factor-1 (Bif-1) in Colorectal adenocarcinoma. Cancer. 2008;113: 2665–2670.
Runkle KB, Meyerkord CL, Desai NV, Takahashi Y, Wang HG. Bif-1 suppresses breast cancer cell migration by promoting EGFR endocytic degradation. Cancer Biol Ther. 2012;13:956-66.
Coppola D, Oliveri C, Sayegh Z, et al. Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer. 2008; 6:117-21.
Liu Y, Takahashi Y, Desai N, et al. Bif-1 deficiency impairs lipid homeostasis and causes obesity accompanied by insulin resistance. Sci Rep. 2016; 6:20453.
Wang DB, Kinoshita Y, Kinoshita C, et al. Loss of endophilin-B1 exacerbates Alzheimer's disease pathology. Brain 2015;138:2005-19.
Takahashi Y, Hori T, Cooper TK, et al. Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy. Blood. 2013;121:1622-32.
Lee JW, Jeong EG, Soung YH, et al. Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas. Pathology.2006; 38:312-5.
Xu L, Wang Z, He SY, et al. Bax-interacting factor-1 inhibits cell proliferation and promotes apoptosis in prostate cancer cells. Oncol Rep 2016; 36:3513-3521.
Kim SY, Oh YL, Kim KM, et al. Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers. Pathology. 2008; 40:553-7.
Coppola D, Helm J, Ghayouri M, Malafa MP, Wang HG. Down-regulation of Bax-interacting factor 1 in human pancreatic ductal adenocarcinoma. Pancreas.2011; 40:433-7.
Gil J, Ramsey D, Szmida E, et al. The BAX gene as a candidate for negative autophagy-related genes regulator on mRNA levels in colorectal cancer. Med Oncol. 2017; 34:16.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402–8.
Takahashi Y, Coppola D, Matsushita N, et al., Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nature Cell Biology. 2007; 9: 1142–1151.
Ho J, Kong JW, Choong LY, et al. Novel breast cancer metastasis-associated proteins. J Proteome Res. 2009; 8:583-94.
Fan R, Miao Y, Shan X, et al. Bif-1 is overexpressed in hepatocellular carcinoma and correlates with shortened patient survival. Oncol Lett. 2012; 3: 851-854.
Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013; 368:651–62.
White EJ, Martin V, Liu JL, et al. Autophagy regulation in cancer development and therapy. Am J Cancer Res. 2011; 1:362–72.
Marx J. Autophagy: is it cancer's friend or foe? Science. 2006; 312:1160-1.
Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402:672-6.
Takahashi Y, Meyerkord CL, Hori T, et al., Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy, Autophagy. 2011; 7: 61–73.
Mathew R, Karantza-Wadsworth V, White E. Assessing metabolic stress and autophagy status in epithelial tumors. Methods Enzymol. 2009; 453:53-81.